Table 4.
Pairwise Comparisons of Baseline Results.
| Groups | Vs. Abem + NSAI |
vs. Palbo + NSAI |
Vs. Ribo + NSAI |
Vs. Placebo + NSAI |
|
|---|---|---|---|---|---|
| Abem + NSAI |
ICUR, $/QALY | — | Dominate | Dominate | 33,163 |
| INHB, QALY | — | 0.27 | 1.89 | 0.05 | |
| INMB, $ | — | 10,451 | 71,698 | 1849 | |
| Palbo + NSAI |
ICUR, $/QALY | Dominated | — | Dominate | 65,777 |
| INHB, QALY | −0.27 | — | 1.61 | −0.23 | |
| INMB, $ | −10,451 | — | 61,247 | −8602 | |
| Ribo + NSAI |
ICUR, $/QALY | Dominated | Dominated | — | 270,860 |
| INHB, QALY | −1.89 | −1.61 | — | −1.84 | |
| INMB, $ | −71,698 | −61,247 | — | −69,849 | |
| Placebo + NSAI |
ICUR, $/QALY | Dominated | Dominated | Dominated | — |
| INHB, QALY | −0.05 | 0.23 | 1.84 | — | |
| INMB, $ | −1849 | 8602 | 69,849 | — | |
NSAI, letrozole or anastrozole; Abem + NSAI, abemaciclib plus NSAI; Palbo + NSAI, palbociclib plus NSAI; Ribo + NSAI, ribociclib plus NSAI; placebo + NSAI, placebo plus NSAI; ICUR, incremental cost-utility ratio; ICER, incremental cost-effectiveness ratio; INHB, incremental net health benefit; INMB, incremental net monetary benefit; QALY, quality-adjusted life-year.